World’s First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch

2026-02-06 - 00:38

HONG KONG, Feb. 6, 2026 /PRNewswire/ — Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on February 5 that its wholly-owned subsidiary AIM Rongyu’s world’s first independently developed serum-free iterative rabies vaccine has successfully passed the